Bio-Works Expands with WorkBeads affimAb Edge

Bio-Works Technologies, a key player in the bioprocessing sector, has announced the launch of its latest product, WorkBeads affimAb Edge. This innovative offering is set to make significant waves in the Protein A-resin market, which is currently valued between 1 and 1.4 billion USD annually. The market's growth is largely driven by the increasing demand for efficient purification solutions for antibody-based drugs.

Protein A-resins play a crucial role in the purification process, eliminating up to 90 percent of contaminants. Bio-Works' new product, WorkBeads affimAb Edge, promises high capacity, stability, and cost-effectiveness, along with comprehensive regulatory documentation. This positions it as a competitive alternative to current market leaders, catering to the needs of both innovative drug developers and contract manufacturers (CMO/CDMO).

Internally conducted comparative studies have shown that WorkBeads affimAb Edge outperforms the leading product in the segment. The product is developed and manufactured by Korean company PurioGen Inc., which has strong ties with Bio-Works' long-term partner Amicogen. This collaboration is underpinned by a technology license from Bio-Works and is executed through an exclusive OEM agreement, ensuring control over quality, supply, and brand profile.

Lone Carlbom, CEO of Bio-Works, stated, 'With WorkBeads affimAb Edge, we add a differentiated and competitive product to our portfolio and take a strategic step towards increased market share in a high-value segment.' This launch is part of Bio-Works' growth strategy, focusing on high-margin products and global expansion. By combining technical expertise with commercial scalability, the company enhances its relevance in the value chain for modern biopharmaceuticals.

Given the robust market potential and Bio-Works' strategic direction, investors might consider a buy position. The company's focus on innovation and strategic partnerships positions it well for future growth.